The Harvard Drug Group is recalling 678 cartons of Memantine Hydrochloride Extended-Release Capsules (28 mg), a medication used to treat symptoms of Alzheimer's disease. The recall was initiated because routine stability testing showed the drug failed to dissolve properly (low stage 3 dissolution results). This failure means the medication may not release into the body as intended, potentially reducing its effectiveness for patients. These prescription capsules were distributed in Alabama, Florida, Iowa, New York, Ohio, and Texas.
If the medication fails to dissolve according to specifications, the patient may not receive the full intended dose of the drug, which can lead to poorly controlled symptoms of the condition being treated. No specific injuries or adverse events have been reported to date.
Contact your healthcare provider or pharmacist for guidance. Return any unused product to the pharmacy for a refund
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.